51. 全身性強皮症 Scleroderma Clinical trials / Disease details


臨床試験数 : 523 薬物数 : 608 - (DrugBank : 156) / 標的遺伝子数 : 113 - 標的パスウェイ数 : 214

  
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04837131
(ClinicalTrials.gov)
April 28, 20215/4/2021A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease PatientsA Phase 2 Open-Label Pilot Study of the Safety and Tolerability of Ixazomib Administered Orally to Patients With Scleroderma-Related Interstitial Lung DiseaseSystemic Sclerosis;Scleroderma;Diffuse Systemic Sclerosis;Diffuse Scleroderma;Diffuse Cutaneous Systemic Sclerosis;Diffuse Cutaneous Scleroderma;Progressive Systemic Sclerosis;Progressive Scleroderma;Scleroderma, Systemic;Scleroderma, Diffuse;Progressive;Systemic Sclerosis, Diffuse;Systemic; Sclerosis, Progressive;Scleroderma of Lung;Scleroderma With Pulmonary Involvement;Systemic Sclerosis Pulmonary;Systemic Sclerosis With Lung Involvement;Interstitial Lung Disease;Pulmonary Fibrosis InterstitialDrug: IxazomibW. Leroy GriffingNULLRecruiting18 YearsN/AAll12Phase 2United States